DIFFUSION PHARMACEUTICALS INC. CONVERTIBLE 6.0% PROMISSORY NOTE

EX-4.1 2 ex4-1.htm EXHIBIT 4.1 ex4-1.htm

Exhibit 4.1

 

 

THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW. NO SALE, TRANSFER, PLEDGE, ASSIGNMENT OR OTHER DISPOSITION OF THIS NOTE OR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF SHALL BE VALID OR EFFECTIVE UNLESS (A) SUCH TRANSFER IS MADE PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAW, OR (B) THE HOLDER SHALL DELIVER TO THE COMPANY AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY ACCEPTABLE TO THE COMPANY THAT SUCH TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. ANY CONVERSION OF THIS NOTE SHALL BE IRREVOCABLE AND THE HOLDER SHALL HAVE NO RIGHTS TO REQUIRE THE COMPANY TO REPURCHASE OR OTHERWISE REACQUIRE SUCH SECURITIES.

 

DIFFUSION PHARMACEUTICALS INC.
 

CONVERTIBLE 6.0% PROMISSORY NOTE

 

September 27, 2016 

 

Charlottesville, Virginia

 $[______]

                                                      

 

Diffusion Pharmaceuticals Inc., a Delaware corporation (the “Company”), for value received, hereby promises to pay the undersigned investor or registered assigns (the “Holder”) on September 27, 2017 (the “Maturity Date”), at the principal offices of the Company located at 2020 Avon Court #4, Charlottesville, Virginia 22902 (the “Principal Office”), the principal sum of $[_____], plus interest on such amount accruing at a rate of 6.0% per annum, unless and until the Company’s obligation with respect to the payment of such principal sum shall be discharged as herein provided. Unless converted as set forth in paragraph 3, principal and accrued interest shall be payable in cash on the Maturity Date.

 

1.

Ranking.

 

This Note will constitute a general, unsecured obligation of the Company

 

2.

Events of Default.

 

(a)     An “Event of Default” shall mean (x) the failure of the Company to pay any of its payment obligations under this Note when due, or (y) the Company admits in writing its inability to pay its debts generally as they become due; makes an assignment for the benefit of its creditors; consents to or acquiesces in the appointment of a receiver, liquidator, fiscal agent, or trustee of itself or any substantial portion of its property; files a petition under bankruptcy or other laws for the relief of debtors; consents to any reorganization, arrangement, workout, liquidation, dissolution, or similar relief; or any court adjudicates the Company as bankrupt and such adjudication shall remain unvacated, not set aside, or unstayed for an aggregate of 60 days, whether or not consecutive.

 

 
 

 

Page 2

  

 

(b)     In the event of default in payment under the terms of paragraph 2(a)(x) as the same becomes due and such default is not cured within thirty (30) days after written notice thereof is received by the Company, or default under the terms of paragraph 2(a)(y) and such default is not cured within forty five (45) days after written notice thereof is received by the Company, and at any time during the continuation of any such Event of Default, the Holder may, upon notice to the Company, (i) declare the aggregate outstanding amount of this Note to be immediately due and payable and may exercise any rights or remedies permitted under applicable law and/or (ii) elect to convert this Note, in whole or in part, together with accrued but unpaid interest, into shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a price per Share equal to $3.50 (as may be adjusted pursuant to the terms of paragraph 5 below, the “Conversion Price”) . In connection with the foregoing, the Company waives notice of intent to demand, demand, presentment for payment, notice of nonpayment, protest, notice of protest, grace, notice of dishonor, notice of intent to accelerate, and all other notices, except those with respect to defaults as described within this paragraph.

 

3.

Conversion.

 

(a)     At any time and from time-to-time prior to the Maturity Date, the Holder may elect to convert this Note, in whole or in part, together with accrued but unpaid interest, into Shares at a price per Share equal to the Conversion Price. Upon conversion, Holder shall not be subject to any restrictions regarding the sale of such stock, other than restrictions imposed by applicable securities laws and that certain Settlement Agreement, dated as of the date hereof, by and among the Company, the Holder and the other parties thereto.

 

(b)     In the event of a Change of Control of the Company, the Holder may, upon notice to the Company, (x) declare the aggregate outstanding amount of this Note to be immediately due and payable and may exercise any rights or remedies permitted under applicable law and/or (y) elect to convert this Note, in whole or in part, together with accrued but unpaid interest as if such conversion took place on the Maturity Date, into Shares at a price per Share equal to the Conversion Price, with such conversion to be effective immediately prior to the effective time of the Change of Control. In connection with the foregoing, the Company waives notice of intent to demand, demand, presentment for payment, notice of nonpayment, protest, notice of protest, grace, notice of dishonor, notice of intent to accelerate, and all other notices. For purposes of this paragraph, the term “Change of Control” shall mean (i) a merger or consolidation in which the holders of the Company’s common stock immediately prior to the transaction do not own, directly or indirectly, more than 50% of the equity interests of the surviving company; (ii) the acquisition of more than 50% of the Company's outstanding common stock by a single person, entity or group or persons or entities acting in concert, or (iii) the sale or transfer of all or substantially all of the assets of the Company.

 

(c)     If the Holder elects to convert this Note into Shares pursuant to the terms hereof, the Holder shall notify the Company (such notice, the “Conversion Notice”) of the conversion. The effective date of the conversion shall be the date of the Conversion Notice, except as otherwise set forth in Section 3(c) above. On conversion of this Note, (i) the Holder shall surrender this Note at the Principal Office, (ii) such conversion shall be irrevocable and the Holder shall have no rights to require the Company to repurchase or otherwise reacquire such securities, and (iii) the Company shall issue and deliver to the Holder a new note or notes reflecting the portion, if any, of the principal amount hereof not so converted, which new note or notes shall be subject to the same terms and conditions as this Note. Prior to the conversion of this Note, Holder shall not be entitled by reason of the Holder’s status as a holder of this Note to any rights of a stockholder of the Company.     

 

 
2

 

Page 3

  

 

4.

Notices.

 

Any notice required by this Note shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile or email if sent during normal business hours of the recipient; if not, then on the next business day, (c) five (5) days after having been sent by certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices shall be addressed to the Holder at the address of the holder appearing on the books of the Company. Any notices shall be addressed to the Company at its Principal Office. Any party may change the location at which it will receive notice hereunder by providing the other party with notice of such change pursuant to the provisions of this paragraph 5.

 

5.

No Dilution or Impairment.

 

If the Company, at any time on or after the date hereof: (i) makes a distribution or distributions on its Shares or any other equity or equity equivalent securities payable in Shares (which, for avoidance of doubt, shall not include any Shares issued by the Company pursuant to the conversion of any other convertible promissory notes of the Company or its subsidiaries), (ii) subdivides outstanding Shares into a larger number of Shares, (iii) combines outstanding Shares into a smaller number of Shares, or (iv) issues by reclassification of Shares any ownership interest of the Company, then in each case the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of Shares outstanding immediately before such event and of which the denominator shall be the number of Shares immediately after such event. Any adjustment made pursuant to this paragraph 6(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such distribution or shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

6.

Miscellaneous.

 

(a)     This Note is nonnegotiable, and no transfer, assignment or other disposition of this Note or of any interest or right herein or in the indebtedness evidenced hereby shall be effected except that the Note is transferable to the heirs or spouse of Holder in the event of death or disability of Holder.

 

(b)     The Company may consider and treat the person in whose name this Note shall be registered as the absolute owner thereof for all purposes whatsoever and the Company shall not be affected by any notice to the contrary. Without the consent of the Company or except upon transfer by operation of law, this Note shall be non-transferable. Registration of any new owners shall take place upon presentation of this Note to the Company at its Principal Office, together with a duly authenticated assignment. In case of transfer by operation of law, the transferee agrees to notify the Company of such transfer and of his or her address, and to submit appropriate evidence regarding the transfer so that this Note may be registered in the name of the transferee. This Note is transferable only on the books of the Company. Notice sent to any registered owner shall be effective as against all the Holders or transferees of this Note not registered at the time of sending the communication.

 

(c)     All payments of interest and principal shall be in lawful money of the United States of America.

 

 
3

 

Page 4

 

 

(d)     The Company agrees to pay the reasonable costs in collecting and enforcing this Note, including reasonable and documented attorneys’ fees.

 

(e)     THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES THEREOF. VENUE FOR ANY DISPUTE ARISING HEREUNDER SHALL BE PROPER EXCLUSIVELY IN THE DELAWARE CHANCERY COURT.

 

(f)     No recourse shall be had for the payment of the principal of this Note against any past, present or future member, manager, officer, director, agent or attorney of the Company, or of any successor Company, either directly or through the Company or any successor Company, all such liability of the members, managers, officers, directors, agents and attorneys being waived, released and surrendered by the Holder hereof by the acceptance of this Note.

 

(g)     This Note may not be altered, amended, modified or waived except by a written instrument signed by the Company and the Holder. 

 

 
4

 

Page 5

 

 

IN WITNESS WHEREOF, the Company has caused this Note to be issued in its name by its authorized officer on the date first set forth above.

 

 

THE COMPANY:

 

DIFFUSION PHARMACEUTICALS INC.

 

 

By:____________________________                    
Name: David G. Kalergis, MBA/JD

Title: Chief Executive Officer

 

 

HOLDER:

 

[___________]

 

 

_________________________        

 

 

 

 

5